Printer Friendly

CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS OF NOVEL ANTI-STROKE COMPOUND

 CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS
 OF NOVEL ANTI-STROKE COMPOUND
 CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that it has initiated clinical trials of its N-Methyl-D-Aspartate (NMDA) ion-channel blocker, CNS 1102, for the prevention of brain damage in stroke and head injury, in the United Kingdom. The trials will be Phase Ia dose ranging safety studies conducted at the Western Infirmary associated with the University of Glasgow in Scotland, in healthy human volunteers. The clinical development of the compound has been accelerated due to the promising safety and efficacy results of recently completed preclinical studies.
 "We are excited by the emerging profile of this compound, and pleased to have passed the first major milestone in the clinical development process well ahead of schedule," said Dr. Elkan Gamzu, president and chief operating officer. "This study will be a double- blind assessment of the safety and tolerance of CNS 1102 and will be conducted by standards equivalent to those required by the Food and Drug Administration."
 The interruption of blood flow to the brain following stroke or head injury causes an excess of calcium to flow into nerve cells via the NMDA ion-channel. This overload initiates a biochemical process that results in the continued death of cells. CNS 1102 blocks the NMDA ion-channel, preventing the calcium overload and protecting the nerve cells from destruction. There are approximately 500,000 victims of stroke each year in the U.S. and an equivalent number of people who suffer a head injury, and currently no drug is available to limit the extent of the irreversible brain damage that occurs after stroke or head injury.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders, including stroke, traumatic brain injury, schizophrenia, diabetic peripheral neuropathies and amyotrophic lateral sclerosis (Lou Gehrig's disease).
 -0- 8/11/92
 /CONTACT: Elkan Gamzu, president, COO, 617-225-0600, ext. 116; or John T. Smith, manager, corporate communications, 617-225-0600, ext. 151/
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU:


DH -- NE002 -- 8852 08/11/92 09:39 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:358
Previous Article:INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992
Next Article:DCA ANNOUNCES RLN 1.1
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE BEGINS MULTI-CENTER CLINICAL TRIALS OF NEW PSYCHIATRIC PRODUCT
PRECLINICAL DATA ON NEUROPROTECTIVE COMPOUND FROM CAMBRIDGE NEUROSCIENCE PUBLISHED IN "NEUROLOGY"
CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS
CAMBRIDGE NEUROSCIENCE DISCONTINUES ECTAPRAM, AN IN-LICENSED ORPHAN DRUG PRODUCT, AND REDIRECTS RESOURCES TO STROKE AND GROWTH FACTOR PROGRAMS
CAMBRIDGE NEUROSCIENCE INITIATES CLINICAL TRIALS OF CERESTAT FOR TRAUMATIC BRAIN INJURY; FIRST U.S. TBI TRIAL BEGINS AT HERMANN HOSPITAL
CAMBRIDGE NEUROSCIENCE BEGINS MULTINATIONAL DOSE-FINDING STUDY OF CERESTAT(TM) IN STROKE PATIENTS
CAMBRIDGE NEUROSCIENCE AND BOEHRINGER INGELHEIM INITIATE PIVOTAL TRIAL OF CERESTAT IN STROKE
Cambridge NeuroScience Initiates Second Phase I Study of CNS 5161 and Announces Successful Completion of First Phase I Trial
Cambridge NeuroScience Will Not Restart Accrual in Stroke Trial
Cambridge NeuroScience Reports Positive Results From Pain Study

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters